Scandinavian Real Heart AB (SE:HEART)
:HEART
Want to see SE:HEART full AI Analyst Report?
HEART Stock Chart & Stats
kr25.80
kr0.30(2.04%)
At close: 4:00 PM EST
kr25.80
kr0.30(2.04%)
Day’s Range― - ―
52-Week Rangekr12.06 - kr29.89
Previous CloseN/A
Volume1.18K
Average Volume (3M)7.92K
Market Cap
kr149.56M
Enterprise Valuekr74.81M
Total Cash (Recent Filing)kr27.94M
Total Debt (Recent Filing)kr5.40M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume3,221
30 Day Avg. Volume7,918
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Modest DebtLow reported leverage provides durable financial flexibility for a capital-intensive medtech developer. With limited fixed interest obligations, the company can prioritize clinical milestones and regulatory work without large debt service constraints, reducing near-term insolvency risk.
Clear Product Focus (Realheart TAH)A single, clearly defined flagship device aligns R&D, clinical and regulatory efforts around one commercial pathway. Focused development can accelerate learning, reduce wasted spend across programs and improve clarity for partners and regulators over the medium term.
Concentrated R&D PipelineA concentrated pipeline around an implantable total artificial heart sharpens management priorities and resource allocation. For a small specialist team this can yield operational efficiency in trial execution and clearer go-to-market planning if clinical progress continues.
Bears Say
Pre-revenue With Persistent LossesBeing effectively pre-revenue with sustained deep losses is a structural risk: the business must deliver clinical and regulatory milestones to ever achieve commercial sales. Continued operating losses increase execution risk and lengthen the time until self-sustaining cash generation.
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flow signals ongoing funding dependence. Over a multi-quarter horizon this constrains the company’s ability to scale trials or commercial prep without external capital, raising dilution and execution risk if markets tighten.
Shrinking Equity Base / Dilution RiskA materially declining equity base reflects prior financing and cumulative losses, reducing the balance-sheet cushion. This makes the firm more reliant on new capital infusions to fund operations, increasing shareholder dilution risk and exposing strategy to capital market conditions.
HEART FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was kr12.06 and its highest was kr29.89 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is kr149.56M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is Aug 28, 2026 which is in 96 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Currently, no data Available
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 8,497,797 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in SE:HEART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ) designs and develops an artificial heart. It engages in developing Realheart TAH to treat advanced stage heart failure. It also develops RealVAD, PulsePump, and Sternal Prosthesis products. The company was incorporated in 2007 and is based in Västerås, Sweden.